The divestiture streamlines Resmed's portfolio but provides no deal value or financial details. Monitor Resmed's Q4 FY2026 regulatory filings for sale price and any gain/loss recognition. The stock may see modest pressure if the sale price implies a small or distressed valuation; absence of price disclosure is a slight negative signal.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 8 $205.84entry
- T+1 · 4mo ago +1.27%α +0.42% · $208.45
- T+5 · 4mo ago −6.23%α −7.10% · $193.01
- T+20 · 3mo ago +8.84%α +5.56% · $224.03
- T+60 · 7w ago +7.44%α +4.94% · $221.15
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Resmed has agreed to sell its long-term care software business MatrixCare to Frazier Healthcare Partners. The move focuses Resmed on its core sleep, breathing, and home-based healthcare strategy but the press release does not disclose the sale price, implying it may be small relative to Resmed's $31.7B market cap. The transaction is expected to close in Q1 FY2027, subject to regulatory approvals.
Key Facts
- Resmed entered a definitive agreement to sell its MatrixCare business to Frazier Healthcare Partners.
- MatrixCare serves over 15,000 providers in skilled nursing, senior living, long-term care, and home health/hospice.
- The transaction is expected to close in Q1 of fiscal year 2027 (approximately October-December 2026).
- The sale price is not disclosed in the press release.
- The divestiture excludes Resmed's other software businesses Brightree (US) and MEDIFOX DAN (Germany).
- Frazier Healthcare Partners is a private equity firm that has raised over $11B and invested in more than 200 healthcare companies.
Financial Impact
Sale price undisclosed; MatrixCare's revenue contribution is not stated, so the financial magnitude relative to Resmed's $31.7B market cap cannot be determined.
Risk Factors
- Undisclosed sale price may be small relative to market cap or imply a discounted valuation.
- Regulatory approvals could delay or block the transaction.
- MatrixCare's departure removes a diversified revenue stream in the long-term care software market.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3323651 |
Track record
19 reports on RMD
4 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +28.97% at T+60 after the Jun 1, 2026 report. 6 of 6 went positive at some point.
Filters
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $234.11 Now $238.19 +1.74% settles Dec 9
- Oct 29, 202618d ago 8-K Bullish 6/10 No price data
- Oct 29, 202618d ago Press Release Bullish 6/10 Entry $229.94 Now $238.19 +3.59% settles Nov 30
- Oct 16, 20264w ago Institutional Cluster Bearish 4/10 Entry $238.88 to $238.19 Now $238.19 +0.29% ▲ +0.29% −3.17% vs SPY
- Oct 7, 20265w ago 144 Neutral 3/10 Entry $226.73 to $240.51 Now $238.19 +5.05% ▲ +6.08% +11.37% vs SPY
- Oct 1, 20266w ago DEFA14A Neutral 2/10 Entry $218.89 to $229.94 Now $238.19 +8.82% ▲ +5.05% +6.86% vs SPY
- Oct 1, 20266w ago DEF 14A Neutral 4/10 Entry $218.89 to $252.83 Now $238.19 +8.82% ▲ +15.51% +17.31% vs SPY
- Oct 1, 20266w ago Press Release Neutral 1/10 Entry $218.89 Now $238.19 +8.82% No price data
- Sep 10, 20269w ago Insider Cluster Neutral 4/10 Entry $219.58 to $226.73 Now $238.19 +8.48% ▲ +3.26% +1.13% vs SPY
- Aug 11, 202613w ago Insider Cluster Neutral 2/10 Entry $224.84 to $219.95 Now $238.19 +5.94% ▼ −2.17% −1.12% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers